WORCESTER, Mass., Sept. 16, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, has reached the enrollment milestone of more than two hundred subjects in the company's pivotal Phase III clinical trial of Generex Oral-lyn(tm), its flagship proprietary prandial oral insulin spray product. There are 74 sites in the United States, Canada, Bulgaria, Poland, Romania, Russia and Ukraine actively screening and enrolling subjects.
